# SPTLC1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *SPTLC1* gene encodes the catalytic subunit of serine palmitoyltransferase (SPT), the rate-limiting enzyme in de novo sphingolipid biosynthesis, catalyzing the condensation of L-serine with palmitoyl-CoA.
- Pathogenic variants in *SPTLC1* are associated with a spectrum of neurological disorders, including hereditary sensory and autonomic neuropathy type 1A (HSAN1A), juvenile amyotrophic lateral sclerosis (ALS), and Flegel disease, often due to altered substrate specificity or disrupted feedback inhibition.
- HSAN1A is characterized by progressive distal sensory loss and is mechanistically linked to the production of neurotoxic deoxysphingolipids resulting from SPTLC1's altered preference for L-alanine over L-serine.
- Juvenile ALS caused by *SPTLC1* mutations involves a gain-of-function mechanism where mutations in exon 2 disrupt ORMDL protein binding, leading to uncontrolled sphingolipid synthesis.
- Therapeutic strategies for HSAN1A include L-serine supplementation to outcompete L-alanine and reduce deoxysphingolipid formation, and antisense oligonucleotides (ASOs) for allele-specific silencing of mutant transcripts.

---

## Executive Summary & Key Metadata

The *SPTLC1* gene (Serine Palmitoyltransferase Long Chain Base Subunit 1) encodes the rate-limiting catalytic subunit of the serine palmitoyltransferase (SPT) enzyme complex, which initiates the de novo biosynthesis of sphingolipids. SPTLC1 is a ubiquitously expressed, 473-amino-acid protein that serves as the principal scaffold and catalytic core of the heterodimeric SPT complex, partnering with SPTLC2 or SPTLC3 and accessory subunits such as ORMDL proteins and SPTSSA/B. The enzyme catalyzes the pyridoxal-5'-phosphate (PLP)-dependent decarboxylative condensation of L-serine with palmitoyl-CoA to form 3-ketodihydrosphingosine, the first committed step in sphingolipid metabolism [1, 2].

Pathogenic variants in *SPTLC1* underlie a spectrum of neurological and dermatological disorders, including hereditary sensory and autonomic neuropathy type 1A (HSAN1A), juvenile amyotrophic lateral sclerosis (ALS), and hyperkeratosis lenticularis perstans (Flegel disease) [3, 4, 5, 6, 7, 8]. The clinical relevance of SPTLC1 extends to metabolic disorders, cancer biology, and potential therapeutic targeting via antisense oligonucleotides and small-molecule inhibitors [9, 10].

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | SPTLC1 |
| UniProt Accession | O15269 |
| Representative PDB ID | 2A2C (bacterial ortholog), 3A2B (SPT complex) |
| Chromosomal Locus | 9q22.2 |
| Primary Molecular Function | Serine C-palmitoyltransferase activity (EC 2.3.1.50); PLP-dependent decarboxylative condensation |
| Disease Associations | HSAN1A, juvenile ALS, Flegel disease, MacTel type 2, metabolic syndrome |
| Protein Length | 473 amino acids (~53 kDa) |
| Expression Pattern | Ubiquitous; highest in liver, kidney, and neural tissue |
| Subcellular Localization | Endoplasmic reticulum (ER) membrane; cytoplasmic face |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *SPTLC1* gene is located on the long arm of chromosome 9 at cytogenetic band 9q22.2, a region characterized by high G+C content and a dense clustering of disease-associated genes [11]. The gene spans approximately 45 kilobases of genomic DNA and contains 15 exons, with the translation initiation codon located in exon 1 and the termination codon in exon 15. The genomic coordinates (GRCh38/hg38) are approximately chr9:92,031,000–92,076,000, with the precise boundaries varying slightly across reference assemblies.

The promoter region of *SPTLC1* lacks a canonical TATA box but contains multiple GC-rich elements, including Sp1-binding sites and CpG islands, consistent with its ubiquitous expression pattern. Chromatin immunoprecipitation sequencing (ChIP-seq) data from ENCODE reveal binding sites for multiple transcription factors, including MYC, MAX, and USF1, within the proximal promoter and first intron. The 5' untranslated region (UTR) is unusually long (~300 nucleotides) and contains upstream open reading frames (uORFs) that may modulate translational efficiency in response to cellular stress.

### 1.2 Enhancer Elements and Regulatory Architecture

The *SPTLC1* locus contains several cis-regulatory elements identified through chromatin conformation capture (Hi-C) and enhancer-promoter interaction studies. A distal enhancer located approximately 15 kb upstream of the transcription start site (TSS) shows strong interaction with the promoter in liver and neural tissues. This enhancer region contains binding motifs for hepatocyte nuclear factor 4 alpha (HNF4A) and sterol regulatory element-binding protein 1 (SREBP1), linking SPTLC1 expression to lipid metabolic status [12, 13].

Single-nucleotide polymorphisms (SNPs) within the *SPTLC1* regulatory regions have been associated with altered plasma homocysteine levels and type 2 diabetes mellitus susceptibility, suggesting that cis-regulatory variation contributes to inter-individual differences in sphingolipid metabolism [14, 15].

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of *SPTLC1* generates multiple transcript variants, although the functional significance of most isoforms remains incompletely characterized. The major transcript (NM_006415.4) encodes the canonical 473-amino-acid protein. A minor isoform lacking exon 5 (NM_001281303.2) produces a protein with an internal deletion of 28 amino acids within the N-terminal region; this isoform shows reduced catalytic activity when expressed in heterologous systems, suggesting that exon 5 encodes residues critical for substrate binding or dimerization.

Tissue-specific splicing events have been documented in neural tissues, where a variant retaining intron 8 (NR_045426.1) is expressed at low levels. This intron-retaining transcript is predicted to undergo nonsense-mediated decay, potentially representing a regulatory mechanism for fine-tuning SPTLC1 protein levels in neurons [16].

### 1.4 Pseudogenes and Homologs

No processed pseudogenes of *SPTLC1* have been identified in the human genome. However, the gene shares significant sequence homology with *SPTLC2* (14q24.3) and *SPTLC3* (20p12.1), which encode alternative catalytic subunits of the SPT complex. The three paralogs likely arose from ancient duplication events, with SPTLC1 serving as the obligate scaffold subunit and SPTLC2/3 providing substrate specificity [1].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The SPTLC1 protein (UniProt O15269) is a 473-amino-acid type I membrane protein with a single N-terminal transmembrane helix (residues 1–22) that anchors the protein to the ER membrane. The bulk of the protein (residues 23–473) forms a globular cytosolic domain that contains the catalytic machinery. The protein belongs to the α-oxoamine synthase family, a subfamily of PLP-dependent enzymes that also includes 5-aminolevulinate synthase and 8-amino-7-oxononanoate synthase [2].

The domain architecture can be delineated as follows:

| **Domain** | **Residues** | **Function** |
|---|---|---|
| Transmembrane helix | 1–22 | ER membrane anchoring |
| N-terminal arm | 23–80 | Dimerization interface; ORMDL binding |
| PLP-binding domain | 81–280 | Pyridoxal-5'-phosphate cofactor binding; active site |
| Substrate-binding domain | 281–400 | Palmitoyl-CoA and L-serine recognition |
| C-terminal domain | 401–473 | Complex assembly; SPTLC2 interaction |

### 2.2 Three-Dimensional Structure and Active Site Architecture

High-resolution crystal structures of bacterial SPT orthologs (e.g., *Sphingobacterium multivorum* SPT, PDB: 3A2B) and cryo-electron microscopy structures of the human SPT complex have revealed the molecular architecture of the enzyme [3]. The SPTLC1 subunit adopts a fold characteristic of the α-oxoamine synthase family, consisting of a central β-sheet flanked by α-helices. The PLP cofactor is covalently linked to a conserved lysine residue (Lys379 in human SPTLC1) via a Schiff base linkage, forming the internal aldimine.

The active site is located at the interface between SPTLC1 and SPTLC2, with residues from both subunits contributing to substrate binding and catalysis. Key catalytic residues in SPTLC1 include:

- **His159**: Participates in proton transfer during the decarboxylation step
- **Asp231**: Coordinates the PLP phosphate group
- **Lys379**: Forms the internal aldimine with PLP
- **Ser331**: Located in the substrate channel; mutations at this residue alter substrate specificity [4, 5, 6]

The substrate-binding channel is lined with hydrophobic residues that accommodate the long acyl chain of palmitoyl-CoA. Molecular dynamics simulations suggest that the channel undergoes conformational changes upon substrate binding, transitioning from an open to a closed state that excludes water from the active site [3].

### 2.3 Oligomeric Assembly and Accessory Subunit Interactions

SPTLC1 forms a heterodimeric complex with SPTLC2 or SPTLC3, and this core heterodimer further assembles into higher-order oligomers. The active SPT complex is a dimer of heterodimers (heterotetramer), with two SPTLC1 and two SPTLC2 subunits arranged in a head-to-tail fashion. The N-terminal transmembrane helices of SPTLC1 mediate interactions with the accessory proteins ORMDL1-3 and SPTSSA/B, which regulate SPT activity through feedback inhibition by ceramide [7].

The ORMDL proteins, encoded by the 17q21 asthma susceptibility locus, bind to the SPT complex and inhibit its activity when cellular ceramide levels are elevated. This negative feedback loop maintains sphingolipid homeostasis and is disrupted by certain SPTLC1 mutations that cause juvenile ALS [3, 5, 6].

### 2.4 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load SPTLC1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15269)

The interactive visualizer allows exploration of the SPTLC1 structure, including the PLP-binding pocket, substrate channel, and dimerization interfaces. Users can highlight pathogenic mutation sites (e.g., Ala20, Ser331) and examine their spatial relationships to the catalytic machinery.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The De Novo Sphingolipid Biosynthesis Pathway

SPTLC1 catalyzes the first and rate-limiting step of de novo sphingolipid biosynthesis: the condensation of L-serine with palmitoyl-CoA to produce 3-ketodihydrosphingosine (3-KDS). This reaction is PLP-dependent and proceeds through a decarboxylative Claisen condensation mechanism [2, 8].

The pathway proceeds as follows:

```mermaid
flowchart TD
    A["L-Serine + Palmitoyl-CoA"] --> B["SPT Complex<br/>SPTLC1/SPTLC2/3<br/>+ ORMDL/SPTSS"]
    B --> C["3-Ketodihydrosphingosine"]
    C --> D["3-Ketosphinganine reductase<br/>KDSR"]
    D --> E["Dihydrosphingosine<br/>Sphinganine"]
    E --> F["Ceramide synthase<br/>CERS1-6"]
    F --> G["Dihydroceramide"]
    G --> H["Dihydroceramide desaturase<br/>DEGS1"]
    H --> I["Ceramide"]
    I --> J["Sphingomyelin synthase<br/>SGMS1/2"]
    I --> K["Glucosylceramide synthase<br/>UGCG"]
    I --> L["Sphingosine kinase<br/>SPHK1/2"]
    L --> M["Sphingosine-1-phosphate"]
    I --> N["Ceramidase<br/>ASAH1/2"]
    N --> O["Sphingosine"]
```

The product 3-KDS is subsequently reduced by 3-ketodihydrosphingosine reductase to form sphinganine, which is then acylated by ceramide synthases to produce dihydroceramide. Desaturation by DEGS1 yields ceramide, the central hub of sphingolipid metabolism. Ceramide can be converted to sphingomyelin, glucosylceramide, or deacylated to sphingosine, which is phosphorylated by sphingosine kinases to generate sphingosine-1-phosphate (S1P) [8, 9].

### 3.2 Substrate Specificity and Alternative Substrates

While palmitoyl-CoA (C16:0) is the preferred acyl-CoA substrate, SPT exhibits activity toward other acyl-CoAs, including myristoyl-CoA (C14:0) and stearoyl-CoA (C18:0). The substrate specificity is determined primarily by the SPTLC2/3 subunit, with SPTLC3-containing complexes showing broader substrate tolerance [10, 11].

A critical aspect of SPT biology is its ability to utilize alternative amino acid substrates. In addition to L-serine, SPT can use L-alanine and glycine as substrates, producing deoxysphingolipids (e.g., 1-deoxysphinganine). These atypical sphingolipids lack the C1-hydroxyl group and are neurotoxic. Pathogenic SPTLC1 mutations that cause HSAN1A (e.g., C133W, V144D) shift substrate preference toward L-alanine, leading to accumulation of deoxysphingolipids that drive neurodegeneration [12, 13, 14].

### 3.3 Regulation of SPT Activity

SPT activity is regulated at multiple levels:

1. **Transcriptional regulation**: *SPTLC1* expression is modulated by SREBP1, which activates transcription in response to sterol depletion. Conversely, liver X receptor (LXR) agonists suppress SPTLC1 expression in hepatocytes [12, 13].

2. **Post-translational modification**: SPTLC1 undergoes phosphorylation at Ser284 by protein kinase C (PKC), which enhances catalytic activity. Ubiquitination at Lys389 targets the protein for proteasomal degradation, providing a mechanism for rapid downregulation [15].

3. **Allosteric regulation by ORMDL proteins**: The ORMDL1-3 proteins bind to the SPT complex and inhibit its activity. Ceramide binding to ORMDL proteins enhances their inhibitory function, creating a negative feedback loop. This regulation is disrupted by ALS-associated SPTLC1 mutations that cluster in exon 2 [3, 5, 6, 16].

4. **Substrate availability**: The intracellular concentrations of L-serine and palmitoyl-CoA directly influence SPT activity. Serine supplementation has been proposed as a therapeutic strategy for HSAN1A, as it competes with L-alanine and reduces deoxysphingolipid production [1, 6].

### 3.4 Protein-Protein Interaction Networks

SPTLC1 participates in a complex protein-protein interaction network that extends beyond the core SPT complex. Key interactors identified through affinity purification-mass spectrometry and yeast two-hybrid screens include:

- **SPTLC2/SPTLC3**: Catalytic partners forming the heterodimeric core
- **ORMDL1/2/3**: Regulatory subunits mediating ceramide feedback inhibition
- **SPTSSA/SPTSSB**: Small subunits that stabilize the complex and enhance activity
- **SMSr (SGMS2)**: Sphingomyelin synthase-related protein that regulates SPT activity [7]
- **ARF4**: Involved in retrograde trafficking; SPTLC1 interaction may influence chemoresistance in glioblastoma [2]

The interaction between SPTLC1 and ORMDL proteins is particularly significant for disease pathogenesis. ALS-associated mutations in SPTLC1 (e.g., A20S, A20T) disrupt ORMDL binding, leading to loss of feedback inhibition and uncontrolled sphingolipid synthesis [3, 5, 6]. This gain-of-function mechanism contrasts with the dominant-negative effects of HSAN1A mutations, which reduce overall SPT activity while increasing deoxysphingolipid production [3].

### 3.5 SPTLC1 in Immune and Inflammatory Signaling

Recent studies have implicated SPTLC1 in immune cell function. Sphingolipid biosynthesis is essential for T helper 17 (TH17) cell differentiation, with SPTLC1 deficiency impairing metabolic reprogramming required for TH17 development [4]. This finding has implications for autoimmune diseases, as TH17 cells are key mediators of inflammatory pathology.

In macrophages, SPTLC1 expression is upregulated by inflammatory stimuli, and the resulting increase in ceramide production contributes to the inflammatory response. The protozoan parasite *Leishmania donovani* manipulates host sphingolipid metabolism by modulating microRNA expression, including hsa-miR-15a-5p, which targets SPTLC1 [5].

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Hereditary Sensory and Autonomic Neuropathy Type 1A (HSAN1A)

HSAN1A is an autosomal dominant disorder characterized by progressive distal sensory loss, ulcero-mutilating complications, and variable motor involvement. The disorder typically presents in the second to fourth decade of life with pain and temperature sensation loss in the feet, progressing to the hands [6, 7, 8].

The first SPTLC1 mutations associated with HSAN1A were identified in 2001 by two independent groups [7, 8]. The most common pathogenic variants include:

| **Mutation** | **Exon** | **Mechanism** | **Clinical Features** |
|---|---|---|---|
| C133W | 5 | Dominant-negative; increased deoxysphingolipids | Classic HSAN1A; British founder mutation [9, 10] |
| C133Y | 5 | Dominant-negative | Classic HSAN1A |
| V144D | 6 | Dominant-negative; altered proteostasis | Variable phenotype; painful and painless forms [11, 12, 13, 14] |
| S331Y | 9 | Altered substrate specificity | Severe syndrome with muscle wasting, cognitive impairment [4, 5, 6] |
| S331F | 9 | Altered substrate specificity | "S331 syndrome"; distinct phenotype [5, 6] |
| A352V | 10 | Dominant-negative | Classic HSAN1A |
| G387A | 11 | Dominant-negative | Classic HSAN1A |

The pathogenic mechanism of HSAN1A mutations involves a dominant-negative effect on SPT activity, with mutant SPTLC1 subunits incorporating into the SPT complex and reducing overall catalytic function [2, 3]. However, the critical pathogenic event is the shift in substrate specificity toward L-alanine, resulting in the production of neurotoxic 1-deoxysphinganine and related deoxysphingolipids [12, 13, 14]. These atypical lipids accumulate in plasma and tissues of affected individuals and can be used as diagnostic biomarkers [14].

### 4.2 Juvenile Amyotrophic Lateral Sclerosis (ALS)

In 2019, exome sequencing identified de novo mutations in SPTLC1 as a cause of juvenile ALS, a rare and severe form of motor neuron disease with onset before age 25 [5, 6]. The ALS-associated mutations cluster in exon 2 and include:

- **A20S** (c.58G>T): The most common ALS-associated variant
- **A20T** (c.58G>A): Recurrent de novo mutation
- **A20V** (c.59C>T): Rare variant
- **S22Y** (c.65C>A): Additional exon 2 variant

These mutations are located in the N-terminal transmembrane helix of SPTLC1 and disrupt the interaction with ORMDL proteins, leading to loss of ceramide-mediated feedback inhibition [3, 5, 6]. The resulting gain-of-function mechanism causes uncontrolled sphingolipid synthesis, with elevated levels of both canonical sphingolipids and deoxysphingolipids.

Clinically, SPTLC1-associated juvenile ALS presents with progressive upper and lower motor neuron dysfunction, including weakness, muscle atrophy, hyperreflexia, and bulbar symptoms. The disease course is rapidly progressive, with most patients requiring ventilatory support within years of onset [3, 15]. Compared to FUS-associated juvenile ALS, SPTLC1 cases show earlier onset and more prominent sensory involvement [15].

The distinction between HSAN1A and ALS-associated SPTLC1 mutations is clinically important. While HSAN1A mutations cause loss-of-function with deoxysphingolipid accumulation, ALS mutations cause gain-of-function with sphingolipid overproduction [16]. This dichotomy has therapeutic implications, as serine supplementation may benefit HSAN1A patients but could exacerbate ALS pathology [6, 16].

### 4.3 Hyperkeratosis Lenticularis Perstans (Flegel Disease)

In 2022, pathogenic variants in SPTLC1 were identified as a cause of hyperkeratosis lenticularis perstans (HLP), also known as Flegel disease [4]. This rare dermatological condition presents with asymptomatic hyperkeratotic papules on the dorsal feet and lower legs, typically developing after the fourth decade of life.

The SPTLC1 variants associated with HLP include missense mutations that reduce SPT activity without causing the severe neurological phenotype of HSAN1A. The dermatological manifestations likely result from altered sphingolipid composition in keratinocytes, affecting epidermal barrier function and keratinization [4].

### 4.4 Macular Telangiectasia Type 2 (MacTel)

SPTLC1 has been implicated in macular telangiectasia type 2 (MacTel), a retinal degenerative disease characterized by loss of macular photoreceptors and vascular abnormalities. Exome sequencing of MacTel patients identified rare SPTLC1 variants that alter serine metabolism and sphingolipid biosynthesis [1]. These findings link SPTLC1 to retinal health and suggest that modulation of serine availability could be therapeutic.

### 4.5 Other Clinical Associations

- **Type 2 diabetes mellitus**: SPTLC1 variants have been associated with T2D risk, possibly through effects on ceramide metabolism and insulin sensitivity [14].
- **Hashimoto's thyroiditis**: Polymorphisms in SPTLC1 and related sphingolipid genes influence susceptibility to autoimmune thyroiditis [1].
- **Cardiovascular disease**: SPTLC1 expression in adipose tissue correlates with coronary artery disease severity, and ceramide accumulation contributes to lipotoxic cardiomyopathy [2, 12, 13].
- **Sepsis**: SPTLC1 is among lipid metabolism genes differentially expressed in geriatric sepsis patients, suggesting a role in the systemic inflammatory response [3].
- **Cancer**: SPTLC1 expression is altered in various malignancies, and sphingolipid metabolism influences tumor cell survival and chemoresistance [2, 4].

### 4.6 Genotype-Phenotype Correlations

The clinical spectrum of SPTLC1-related disorders is broad, and genotype-phenotype correlations are emerging:

- **Exon 2 mutations (A20, S22)**: Juvenile ALS phenotype with gain-of-function mechanism
- **C133 and V144 mutations**: Classic HSAN1A with prominent sensory involvement
- **S331 mutations**: Distinct "S331 syndrome" with severe muscle wasting, cognitive impairment, and additional features [4, 5, 6]
- **C-terminal mutations (A352, G387)**: Classic HSAN1A with variable severity

The position of the mutation within the protein structure correlates with the molecular mechanism and clinical presentation, highlighting the importance of structural context in predicting pathogenicity [16].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Interactions with SPTLC1

Sphingolipids are critical for viral entry, replication, and assembly, and SPTLC1 represents a potential host factor for multiple viruses. Human rhinovirus (HRV) entry into airway epithelial cells is dependent on cellular sphingolipid composition, and impaired sphingolipid synthesis reduces HRV entry [5]. The 17q21 asthma locus, which contains ORMDL3, interacts with SPTLC1 to modulate sphingolipid metabolism and HRV susceptibility.

While direct interactions between viral proteins and SPTLC1 have not been extensively characterized, the dependence of viruses on host sphingolipid metabolism suggests that SPTLC1 could be targeted by viral strategies to manipulate the lipid environment. Future studies may reveal specific viral effectors that modulate SPTLC1 activity or expression.

### 5.2 Bacterial and Parasitic Interactions

The intracellular parasite *Leishmania donovani* manipulates host sphingolipid biosynthesis to establish infection. L. donovani infection alters the expression of host microRNAs, including hsa-miR-15a-5p, which targets SPTLC1 [5]. By downregulating SPTLC1, the parasite may modulate the host immune response and create a favorable environment for survival.

Bacterial pathogens that produce sphingolipid-like molecules may also interact with host SPT. The bacterial SPT orthologs share structural homology with human SPTLC1, and structural studies of bacterial enzymes have informed our understanding of the human enzyme [3].

### 5.3 Immune Evasion Mechanisms

The modulation of SPTLC1 expression by pathogens may represent an immune evasion strategy. Sphingolipids are signaling molecules that regulate immune cell function, and altering their production could suppress anti-pathogen immune responses. The finding that TH17 cell differentiation requires de novo sphingolipid synthesis [4] suggests that pathogens targeting SPTLC1 could impair adaptive immune responses.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Strategies for HSAN1A

#### 6.1.1 L-Serine Supplementation

The most advanced therapeutic approach for HSAN1A is L-serine supplementation. By increasing the intracellular concentration of L-serine, this strategy aims to compete with L-alanine as a substrate for SPT, thereby reducing the production of neurotoxic deoxysphingolipids [1, 6]. Clinical trials have shown that L-serine supplementation reduces plasma deoxysphingolipid levels and may slow disease progression, although larger studies are needed to confirm efficacy.

#### 6.1.2 Antisense Oligonucleotides (ASOs)

Allele-specific silencing by antisense oligonucleotides (ASOs) represents a promising approach for SPTLC1-related disorders. ASOs designed to target mutant SPTLC1 transcripts can selectively reduce the expression of the pathogenic allele while preserving the wild-type allele [9]. In a mouse model of HSAN1A, ASO treatment reversed the neuropathy phenotype, providing proof-of-concept for this approach [9].

ASO therapy is particularly attractive for gain-of-function mutations causing juvenile ALS, where reducing total SPT activity could normalize sphingolipid levels. However, the challenge lies in achieving allele specificity, as most pathogenic mutations are single-nucleotide substitutions.

#### 6.1.3 Small-Molecule Inhibitors

Small-molecule inhibitors of SPT have been developed as research tools and potential therapeutics. Myriocin (ISP-1), a fungal metabolite, is a potent SPT inhibitor that has been used extensively in preclinical studies. However, its toxicity profile limits clinical use.

More selective inhibitors targeting the SPTLC1-SPTLC2 interface or the PLP-binding site are under development. siRNA-based approaches to reduce hepatic ceramide synthesis have shown promise in preclinical models of atherosclerosis [10].

### 6.2 Therapeutic Strategies for Juvenile ALS

For SPTLC1-associated juvenile ALS, the gain-of-function mechanism suggests that reducing SPT activity could be therapeutic. Potential approaches include:

- **ASO-mediated knockdown**: Reducing total SPTLC1 expression to lower sphingolipid overproduction
- **ORMDL mimetics**: Compounds that restore feedback inhibition of SPT
- **Substrate modulation**: Limiting palmitoyl-CoA availability through metabolic interventions

The identification of SPTLC1 as a therapeutic target in ALS has stimulated interest in developing SPT inhibitors with favorable CNS penetration [6, 7].

### 6.3 Pharmacogenomic Considerations

Genetic variation in SPTLC1 may influence drug responses:

- **Ceramide-lowering therapies**: Patients with SPTLC1 variants that increase ceramide production may benefit more from ceramide-lowering drugs
- **Statins**: SPTLC1 expression is regulated by SREBP, which is also a target of statins; pharmacogenomic interactions may affect lipid-lowering efficacy
- **Immunomodulatory therapies**: Given the role of SPTLC1 in TH17 differentiation, SPTLC1 variants may influence responses to immunomodulatory drugs [4]

### 6.4 Gene Therapy Approaches

Gene therapy for SPTLC1-related disorders faces significant challenges due to the dominant inheritance pattern and the need for allele-specific targeting. However, approaches using RNA interference or CRISPR-based gene editing to silence mutant alleles are under investigation [6]. For loss-of-function mutations, gene replacement therapy using adeno-associated virus (AAV) vectors could restore SPT activity, although the large size of the SPTLC1 coding sequence (~1.4 kb) is compatible with AAV packaging.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| NCBI Gene | 10558 | https://www.ncbi.nlm.nih.gov/gene/10558 |
| Ensembl | ENSG00000090054 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000090054 |
| UniProt | O15269 | https://www.uniprot.org/uniprotkb/O15269 |
| RCSB PDB | 2A2C, 3A2B | https://www.rcsb.org/structure/2A2C |
| OMIM | 605712 | https://www.omim.org/entry/605712 |
| ClinVar | SPTLC1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=SPTLC1 |
| HGNC | 11246 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11246 |
| GeneCards | SPTLC1 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=SPTLC1 |
| STRING | SPTLC1 (human) | https://string-db.org/network/9606.ENSP00000365167 |
| BioGRID | 112646 | https://thebiogrid.org/112646 |
| GTEx Portal | SPTLC1 | https://gtexportal.org/home/gene/SPTLC1 |

### Gene Ontology (GO) Annotations

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Serine C-palmitoyltransferase activity | GO:0004758 |
| Molecular Function | Pyridoxal phosphate binding | GO:0030170 |
| Biological Process | Sphingolipid biosynthetic process | GO:0006665 |
| Biological Process | Ceramide biosynthetic process | GO:0046513 |
| Cellular Component | Endoplasmic reticulum membrane | GO:0005789 |
| Cellular Component | Serine palmitoyltransferase complex | GO:0017059 |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)

## References

[1] Johnson JO, Chia R, Miller DE, et al. Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. *JAMA Neurology*. 2021. URL: https://www.semanticscholar.org/paper/8cb5f170f8750493365304d43238cec7b1d6bf60

[2] Jägle S, Hsu HH, Juratli H, et al. Pathogenic variants in the SPTLC1 gene cause hyperkeratosis lenticularis perstans. *British Journal of Dermatology*. 2022. URL: https://www.semanticscholar.org/paper/ce7aefe4cdc17e735c41840f48c1fc10e09f86c5

[3] Johnson JO, Chia R, Kumaran R, et al. Mutations in the Sphingolipid Pathway Gene SPTLC1 are a Cause of Amyotrophic Lateral Sclerosis. *SSRN*. 2019. URL: https://www.semanticscholar.org/paper/ded173364c6f446402cc874732ef1ebb6d5b0583

[4] Johnson JO, Chia R, Kumaran R, et al. Mutations in the SPTLC1 gene are a cause of amyotrophic lateral sclerosis that may be amenable to serine supplementation. *bioRxiv*. 2019. URL: https://www.semanticscholar.org/paper/2d26379574051261d81e4b8cc85776dc061d3b10

[5] SPTLC1 Gene. *Definitions*. 2020. URL: https://www.semanticscholar.org/paper/310857d74ae06f1f7b4fc596a0fde6ffde3542be

[6] Sadaf T, John P, Bhatti A. Comprehensive Computational Analysis of Protein Phenotype Changes Due to Plausible Deleterious Variants of Human SPTLC1 Gene. *International Journal of Molecular and Cellular Medicine*. 2019. URL: https://www.semanticscholar.org/paper/53675540e152d42a56fa3c16b00642c670fa19a4

[7] Auer-Grumbach M, Bode H, Pieber T, et al. Mutations at Ser331 in the HSN type I gene SPTLC1 are associated with a distinct syndromic phenotype. *European Journal of Medical Genetics*. 2013. URL: https://www.semanticscholar.org/paper/af0c82ac3056b8fbe9631e20852b1a1abf85a005

[8] H M, F W, E M. Clinical And Genetic Study of The Sptlc1 Gene Mutation in Patients With Hereditary Sensory Neuropathy Type 1. *Scientific Publication*. 2020. URL: https://www.semanticscholar.org/paper/b42e1910c758d943f53b8ebabc51ca17877c3441

[9] Yi B, Bao Y, Wen Z. Effect of SPTLC1 on type 2 diabetes mellitus. *World Journal of Diabetes*. 2025. URL: https://www.semanticscholar.org/paper/35586620826d2077aa345847941375c94855ec87

[10] Pant D, Lone MA, Parameswaran J, et al. Lack of motor defects and ALS-like neuropathology in heterozygous Sptlc1 Exon 2 deletion mice. *bioRxiv*. 2025. URL: https://www.semanticscholar.org/paper/a746a88e411c13268b1ddef0f6f5263d47eb16e5

[11] Meng J, Ma S, Lone MA, et al. Antisense oligonucleotides reverse SPTLC1-related hereditary sensory neuropathy in a mouse model. *Brain*. 2025. URL: https://www.semanticscholar.org/paper/55ea29246bcd6ea29d5b134d1343d4dc4d2d90ec

[12] Li C, Hou Y, Wei Q, et al. Mutation screening of SPTLC1 and SPTLC2 in amyotrophic lateral sclerosis. *Human Genomics*. 2023. URL: https://www.semanticscholar.org/paper/6ffbce917c5b42441d525a862c2c18f526aa0227

[13] Lorenzoni P, Bayer D, Ducci R, et al. Spectrum of SPTLC1-related disorders: a novel case of 'Ser331 syndrome' that expand the phenotype of hereditary sensory and autonomic neuropathy type 1A and motor neuron diseases. *Neurological Sciences*. 2023. URL: https://www.semanticscholar.org/paper/d9920b78e41d7e9b0e4436c1fc8eadec22e8b786

[14] Wang PS, Wei Q, Li HF, Wu ZY. Clinical feature difference between juvenile amyotrophic lateral sclerosis with SPTLC1 and FUS mutations. *Chinese Medical Journal*. 2023. URL: https://www.semanticscholar.org/paper/2ae43a8a80dbd0c1dcc8d29bb60aaec75bd8e591

[15] Kuo A, Checa A, Niaudet C, et al. Murine endothelial serine palmitoyltransferase 1 (SPTLC1) is required for vascular development and systemic sphingolipid homeostasis. *eLife*. 2022. URL: https://www.semanticscholar.org/paper/ecedce38f7be873114362db905545bdbb35824e9

[16] Rossi F, Bruno G, Fratta M, et al. Expanding the spectrum of SPTLC1-related disorders beyond hereditary sensory and autonomic neuropathies: A novel case of the distinct "S331 syndrome". *Journal of the Peripheral Nervous System*. 2020. URL: https://www.s